Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER trial of Ravicti in bestrophin 1-related retinal disease
ISRCTN15509883Phase 2Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of sodium phenylbutyrate in Best vitelliform macular dystrophy (BVMD) and Autosomal Recessive Bestrophinopathy (ARB) (2 arms), sponsored by Manchester University NHS Foundation Trust. Started Mar 2024; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
Best vitelliform macular dystrophy (BVMD)Autosomal Recessive Bestrophinopathy (ARB)
Beyond the preview
Go deeper on ISRCTN15509883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15509883.